Status:
COMPLETED
Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Glioblastoma
Eligibility:
All Genders
40+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether the immunostimulating agent CpG-ODN is effective in the treatment of glioblastoma
Eligibility Criteria
Inclusion
- Glioblastoma
- Karnofsky Performance Status ≥ 60%
Exclusion
- Severe or uncontrolled systemic disease
- Active auto-immune disease
- Uncontrolled epilepsia
- Platelets \< 100 000/mm3 ; or Neutrophils \<500 /mm3 ; or lymphocytes \<300/ mm3
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00190424
Start Date
September 1 2005
End Date
October 1 2010
Last Update
December 13 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Salpetriere
Paris, Paris, France, 75013
2
Hopital Lariboisiere
Paris, Paris, France, 75018